Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray
Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray
复制标题
基于组织芯片的乳腺癌前梯度蛋白2表达鉴定及预后价值
DOI：
10.1177/1010428317713392
复制
发表时间：
2017-07-03
期刊：
影响因子：
--
通讯作者：
Zhang, Bin
中科院分区：
文献类型：
--
作者：
Guo, Jilong;Gong, Guohua;Zhang, Bin
乳腺癌作为导致女性死亡的主要癌症之一，引起了人们的广泛关注。寻找对乳腺癌具有预后价值的潜在生物标志物至关重要。在本研究中，根据主要分子亚群确定了前梯度蛋白2在乳腺癌中的表达模式。通过对Gene Expression Omnibus数据库中的69个样本进行分析，我们发现非三阴性乳腺癌组织中前梯度蛋白2的表达显着高于正常组织和三阴性乳腺癌组织（p < 0.05）。对癌症基因组图谱中总共 622 名患者的数据进行了分析。来自癌症基因组图谱的数据和定量逆转录聚合酶链反应的结果也验证了前梯度蛋白 2 的表达模式。此外，我们进行了免疫组织化学分析。定量结果显示，与正常组织相比，前梯度蛋白2在非三阴性乳腺癌（排除3级）和1+2级（排除三阴性乳腺癌）肿瘤中高表达。与三阴性乳腺癌组织相比，前梯度蛋白2在非三阴性乳腺癌（排除3级）和非三阴性乳腺癌组织中显着高表达（p < 0.01）。此外，与3级组织相比，前梯度蛋白2在1+2级（排除三阴性乳腺癌）和1+2级组织中显着高表达（p < 0.05）。 Fisher精确检验分析显示前梯度蛋白2表达与组织学类型、组织学分级、雌激素状态和孕激素状态显着相关。临床病理变量的单变量分析表明，前梯度蛋白 2 表达、肿瘤大小和淋巴结状态与 1 级和 2 级肿瘤患者的总生存率显着相关。 Cox 多变量分析显示前梯度蛋白 2 是不良结果的假定独立指标 (p = 0.031)。所有这些数据清楚地表明前梯度蛋白2在乳腺癌中高表达，可以被视为乳腺癌预后的假定生物标志物。
Breast cancer has attracted substantial attention as one of the major cancers causing death in women. It is crucial to find potential biomarkers of prognostic value in breast cancer. In this study, the expression pattern of anterior gradient protein 2 in breast cancer was identified based on the main molecular subgroups. Through analysis of 69 samples from the Gene Expression Omnibus database, we found that anterior gradient protein 2 expression was significantly higher in non-triple-negative breast cancer tissues compared with normal tissues and triple-negative breast cancer tissues (p < 0.05). The data from a total of 622 patients from The Cancer Genome Atlas were analysed. The data from The Cancer Genome Atlas and results from quantitative reverse transcription polymerase chain reaction also verified the anterior gradient protein 2 expression pattern. Furthermore, we performed immunohistochemical analysis. The quantification results revealed that anterior gradient protein 2 is highly expressed in non-triple-negative breast cancer (grade 3 excluded) and grade 1 + 2 (triple-negative breast cancer excluded) tumours compared with normal tissues. Anterior gradient protein 2 was significantly highly expressed in non-triple-negative breast cancer (grade 3 excluded) and non-triple-negative breast cancer tissues compared with triple-negative breast cancer tissues (p < 0.01). In addition, anterior gradient protein 2 was significantly highly expressed in grade 1 + 2 (triple-negative breast cancer excluded) and grade 1 + 2 tissues compared with grade 3 tissues (p < 0.05). Analysis by Fisher's exact test revealed that anterior gradient protein 2 expression was significantly associated with histologic type, histological grade, oestrogen status and progesterone status. Univariate analysis of clinicopathological variables showed that anterior gradient protein 2 expression, tumour size and lymph node status were significantly correlated with overall survival in patients with grade 1 and 2 tumours. Cox multivariate analysis revealed anterior gradient protein 2 as a putative independent indicator of unfavourable outcomes (p = 0.031). All these data clearly showed that anterior gradient protein 2 is highly expressed in breast cancer and can be regarded as a putative biomarker for breast cancer prognosis.